Clinical Trials Logo

Periodontal Diseases clinical trials

View clinical trials related to Periodontal Diseases.

Filter by:

NCT ID: NCT05435131 Completed - Clinical trials for Periodontal Diseases

Evaluation of Biomarkers Levels in Gingival Crevicular Fluid, Saliva and Serum for Different Periodontal Diseases

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study is; detection of interleukin(IL)-38, IL-36 gamma(γ) , IL-17 and matrix metalloproteinase(MMP)-9 levels in gingival crevicular fluid (GCF), saliva and serum samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples were obtained from 90 systemically healthy non-smoker individuals with periodontitis (P, n=30), gingivitis(G, n=30) and healthy periodontium (S, n=30). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine IL-38, IL-36γ, IL-17 and MMP-9 levels in the biological samples.

NCT ID: NCT05400538 Completed - Clinical trials for Periodontal Diseases

Probiotics as Adjunct to Non Surgical Periodontal Therapy for Pregnant Women Oral Health

Start date: June 10, 2022
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate the use of probiotics in domiciliary oral hygiene procedures in pregnant women. Patients consenting to participate to the study will undergo periodontal evaluation at the baseline (T0). Then, professional dental hygiene will be performed. Patients will be randomly assigned to: - Trial group: home oral application of Biorepair Peribioma Toothpaste + Biorepair Peribioma mousse twice a day - Control group: home oral application of Biorepair Peribioma Toothpaste Patients will be evaluated after 1 month (T1), 3 (T2) and 6 (T3) months.

NCT ID: NCT05394090 Completed - Stroke Clinical Trials

The Role of Periodontal Diseases and Stimulation of Saliva Secretion in the Acute Phase of Ischemic Stroke

Start date: January 24, 2020
Phase: N/A
Study type: Interventional

Methods: 100 consecutive patients with their first ever ischemic stroke were enrolled in the study. 56 randomly selected patients were subjected to stimulation of salivation, the remaining patients were not stimulated. The severity of the neurological condition was assessed using the NIHSS scale on days 1, 3 and 7 of stroke. The incidence of periodontal diseases was classified using the Hall's scale in the 1st day of stroke. On days 1 and 7 of stroke, the concentration of IL-1beta, MMP8, OPG and RANKL in the patients' saliva was assessed using the Elisa technique. At the same time, the level of CRP and the number of leukocytes in the peripheral blood were tested on days 1, 3 and 7 of the stroke, and the incidence of upper respiratory and urinary tract infections was assessed.

NCT ID: NCT05383794 Completed - Clinical trials for Cardiovascular Diseases

Role of miRNAs in CVD and Periodontitis

Start date: April 1, 2019
Phase:
Study type: Observational

Several micro-RNA plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease. The investigators compared the impact of gingival health, periodontitis (CP), cardiovascular disease or of both diseases (CP +cardiovascular disease) on gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.

NCT ID: NCT05372835 Completed - Clinical trials for Periodontal Diseases

Hypochlorous Acid Mouthwash, Oral Bacteria, and Staphylococcus Aureus

Start date: March 20, 2020
Phase: N/A
Study type: Interventional

Mouthwash is one method of maintain oral health and to reduce the dental plaque and gum inflammation. However, the effects of mouthwash on oral bacteria were not consistent among different brands of them. The aims of present study were to determine the effects of a new designed mouthwash with hypochlorous acid on oral bacteria and Staphylococcus aureus. All participants were invited as a volunteer to attend this study from a private dental clinic and diagnosed by the same dentist. Patients with periodontal diseases were randomized selected as mouthwash group and mouthwash plus dental flossing device (La Chlogen, Taiwan) group. Patients for regular dental visit and without periodontal disease were invited as a control group having mouth rinse with water. After the inform consent was signed, participants completed the intervention study, saliva collection, and a simple survey under the guide of a dental assistant. Saliva samples were collected before and after the intervention for bacterial DNA extraction. A real-time polymerase chain reaction and S. aureus with serial dilutions were applied for the estimation of total oral bacterial count (TOBC) in saliva. An in vitro assay with CCK-8 reagent was apply to test the antibacterial ability of mouthwash.

NCT ID: NCT05336396 Completed - Clinical trials for Periodontal Diseases

Impact of Brief Motivational Interviewing on Periodontal Clinical Outcomes: a 3-year Post-trial Follow-up

BMI
Start date: May 20, 2019
Phase: N/A
Study type: Interventional

The objective is a 3-year follow-up clinical trial to evaluate longitudinal indicators of periodontal disease (plaque score, bleeding on probing (BOP), and gingival index (GI)) in 58 participants who completed NCT03571958. These participants were randomized to a brief motivational (BMI) test group or a traditional oral hygiene instruction (OHI) group for a 1-year clinical trial from 2018-2020. In addition, analysis of retrospective data to determine health topics that emerge from the behavior change strategy of BMI compared to traditional OHI by transcription of audio recordings from 2018-2020.

NCT ID: NCT05325905 Completed - Clinical trials for Periodontal Diseases

Analysis of Gingival Crevicular Fluid

GCF
Start date: October 2014
Phase:
Study type: Observational

The purpose of this study was to investigate and compare GCF interleukin-1β (IL-1β), interleukin-10 (IL-10), interleukin-36γ (IL-36γ) levels in patients with healthy (H), gingivitis (G) and chronic periodontitis (CP) status.

NCT ID: NCT05314192 Completed - Clinical trials for Myocardial Infarction

Non-invasive Assessment of Inflammatory Markers MIP-1 Alpha and IL-6 in Saliva of Post Myocardial Infarction and Stage 4 Periodontitis Patients

Start date: March 1, 2021
Phase:
Study type: Observational

Periodontitis is an immunoinflammatory disease caused by microorganisms leading to sequential loss of the supporting structures of periodontium, resulting in periodontal pocket formation, gingival recession eventually leading to tooth loss.[1] A bacterial plaque is formed during the destructive changes of the periodontium which initiates a host of inflammatory and immune responses.[2] These inflammatory responses may also cause an increase in inflammatory activities in atherosclerotic lesions in the coronary arteries resulting in the increased risk of cardiovascular events like myocardial infarction.[3] Myocardial infarction (MI) is a cardiovascular condition that occurs when there is deprivation of oxygen in the heart muscle is due to the sudden interruption of the blood supply resulting from the coronary artery blockage by a plaque causing myocardial ischemia and cell death. Inflammation is pivotal in the initiation and progression of atherosclerosis. Various cytokines and chemokines are released during inflammation.[4] These inflammatory markers may have diagnostic potential for the detection of various inflammatory diseases.[5] Macrophages secrete macrophage inflammatory protein-1 alpha (MIP-1 alpha) which recruits inflammatory cells, inhibits stem cells, and activates bone resorption cells.[6] Interleukin-6 (IL-6) is produced in response to tissue injury and infection and contributes to the differentiation of B cells, the proliferation of T cells, and bone resorption.[7] The levels of these inflammatory markers are seen to be increased in inflammatory conditions, which include myocardial infarction and stage 4 periodontitis. Therefore, this study aims to assess the levels of these inflammatory markers in patients with myocardial infarction and periodontitis.

NCT ID: NCT05312606 Completed - Clinical trials for Periodontal Diseases

Domiciliary Use of Hyaluronic Acid Gel Solutions vs Domiciliary Use of Chlorhexidine Mouthwash 0,20% for the Management of Periodontal Patients

Start date: April 4, 2022
Phase: N/A
Study type: Interventional

Brief Summary: This is a randomized controlled clinical trial (RCT). After signing the informed consent, patients satisfying the inclusion criteria will undergo supragingival and subgingival professional oral hygiene of both arches performed with ultrasonic instrumentation, manual instrumentation with Gracey curettes and air polishing with glycine powder. After that, the sample will be randomly divided into 2 groups based on the domiciliary assigned treatment: - Aftoral® Oral Gel solution with Hyaluronic Acid, Xylitol and glycerophosphoinositol as a domiciliary application for 15 days. - Unidea® Chlorhexidine digluconate Mouthwash 0,20% administration as a domiciliary application for 15 days. The study will last 6 months. Patients will be visited at: T0, after 1 month from T0 (T1), after 3 months (T2), after 6 months (T3). Professional hygiene will be performed again at T2 and T3. At each recall session were collected a satisfaction questionnaire of the products (taste, smell, consistency, persistence and ease of application) and the following periodontal clinical indices, using a Periodontal probe on each site: - Gingival Recession (R) - PPD (Probing Pocket Depth), - BOP% (Bleeding on Probing), - CAL (Clinical Attachment Level), - PCR% (Plaque Control Record), - Tooth Mobility.

NCT ID: NCT05281848 Completed - Smoking Clinical Trials

Effect of Smoking and Periodontal Therapy on Salivary and Gingival Crevicular IL-17 and IL-35

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Periodontal diseases are among the major causes of tooth loss. Smoking may play a role as a contributing factor in the development of periodontitis by reducing the immune response. The role of cytokines in the pathogenesis of periodontal disease is clearly indicated in the literature; it has been shown that microorganisms that cause periodontal disease cause cytokine increase in saliva, gingival tissue and gingival crevicular fluid. Among these cytokines, interleukin (IL) -17 is proinflammatory and IL-35 is antiinflammatory and has been associated with periodontal disease.